--- title: "Bristol Myers Squibb Announces Positive Phase 1 Results for Novel EGFRxHER3 Bispecific ADC in Metastatic NSCLC at ESMO 2025" description: "Bristol Myers Squibb announced positive Phase 1 results for its EGFRxHER3 bispecific ADC, izalontamab brengitecan (iza-bren), in metastatic non-small cell lung cancer (NSCLC). These findings will be p" type: "news" locale: "en" url: "https://longbridge.com/en/news/260882329.md" published_at: "2025-10-13T10:59:34.000Z" --- # Bristol Myers Squibb Announces Positive Phase 1 Results for Novel EGFRxHER3 Bispecific ADC in Metastatic NSCLC at ESMO 2025 > Bristol Myers Squibb announced positive Phase 1 results for its EGFRxHER3 bispecific ADC, izalontamab brengitecan (iza-bren), in metastatic non-small cell lung cancer (NSCLC). These findings will be presented at the ESMO Congress 2025, highlighting over 50 studies across various cancer types. The results support the FDA’s Breakthrough Therapy designation for iza-bren in advanced EGFR-mutated NSCLC. The congress is scheduled for October 17-21, 2025, in Berlin, Germany. Bristol Myers Squibb Company announced that new data from its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place October 17-21 in Berlin, Germany. The company will showcase results from more than 50 studies, including both company-sponsored and investigator-sponsored research, spanning over 10 cancer types. Among the key presentations is the first disclosure of results from a global Phase 1 study of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFRxHER3 bispecific antibody-drug conjugate, in patients with metastatic non-small cell lung cancer and other solid tumors. These results supported the FDA’s Breakthrough Therapy designation for iza-bren in advanced EGFR-mutated non-small cell lung cancer. All results are scheduled to be presented at the upcoming ESMO 2025 Congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010063007) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) ### Related Stocks - [BMY.US - Bristol Myers Squibb](https://longbridge.com/en/quote/BMY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 百時美施貴寶｜8-K：2025 財年 Q4 營收 125 億美元超過預期 | | [Link](https://longbridge.com/en/news/274969786.md) | | 百時美施貴寶公佈 2025 年第四季度及全年財務結果 | 百時美施貴寶公司發佈了 2025 年第四季度和全年財務業績。盈利新聞稿和投資者演示文稿已在線發佈。分析師和投資者的電話會議定於 2026 年 2 月 5 日上午 8:00（東部時間）舉行，會議回放將在稍後提供。此消息由公共技術公司生成，僅供 | [Link](https://longbridge.com/en/news/274966941.md) | | 市場對百時美施貴寶公司的看法如何？ | 百時美施貴寶的空頭頭寸增加了 3.45%，目前有 3658 萬股被賣空，佔可用股份的 1.8%。覆蓋這些空頭頭寸大約需要 2.27 天。空頭頭寸的增加可能表明投資者的看跌情緒。與同行相比，百時美施貴寶的空頭頭寸比例為 3.44%，較低 | [Link](https://longbridge.com/en/news/272839154.md) | | 解讀百時美施貴寶的期權活動：整體情況如何？ | 百時美施貴寶 (NYSE:BMY) 最近出現了顯著的看漲期權活動，55% 的投資者持看漲態度。該股票的預計價格區間在 25.0 美元到 52.5 美元之間。目前的交易量為 4,025，平均未平倉合約為 1,396。分析師們的意見各不相同，目 | [Link](https://longbridge.com/en/news/271354226.md) | | KG&L Capital Management LLC 持有百時美施貴寶公司價值 107 萬美元的股票 | KG&L Capital Management LLC 在第三季度減少了對百時美施貴寶公司（NYSE:BMY）49.4% 的持股，持有 23,599 股，價值 107 萬美元。其他機構投資者，包括先鋒集團和查爾斯·施瓦布，也調整了他們的持倉 | [Link](https://longbridge.com/en/news/271643261.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.